Press Releases

FDA Advisory Committee Votes on Zynquista™ (Sotagliflozin) as Treatment for Adults with Type 1 Diabetes	Jan 17, 2019
Lexicon Pharmaceuticals to Host Conference Call and Webcast on January 17, 2019 to Discuss Outcome of FDA Advisory Committee Meeting for Sotagliflozin in Type 1 Diabetes	Jan 17, 2019
Lexicon Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Sotagliflozin New Drug Application for the Treatment of Type 1 Diabetes	Jan 17, 2019
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	Dec 21, 2018
Lexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes	Dec 20, 2018
Lexicon Pharmaceuticals Announces Positive Topline Clinical Data for LX9211	Dec 18, 2018
FDA Advisory Committee to Review Investigational Sotagliflozin as Potential Treatment for Type 1 Diabetes	Nov 29, 2018
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	Nov 08, 2018
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	Nov 06, 2018
Lexicon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides a Business Update	Nov 01, 2018